John W.G. van Putten

1.9k total citations · 1 hit paper
23 papers, 1.4k citations indexed

About

John W.G. van Putten is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John W.G. van Putten has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John W.G. van Putten's work include Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (8 papers). John W.G. van Putten is often cited by papers focused on Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (8 papers). John W.G. van Putten collaborates with scholars based in Netherlands, Austria and Poland. John W.G. van Putten's co-authors include Harry J.M. Groen, Remge M. Pieterman, Willem Vaalburg, Gerard H. Koëter, Jan Pruim, J. J. Meuzelaar, V. Fidler, Eduard L. Mooyaart, Bonne Biesma and Thomas Kerbusch and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

John W.G. van Putten

22 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography

2000 864 citations Remge M. Pieterman, John W.G. van Putten et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by John W.G. van Putten

Since Specialization

Citations

This map shows the geographic impact of John W.G. van Putten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W.G. van Putten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W.G. van Putten more than expected).

Fields of papers citing papers by John W.G. van Putten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W.G. van Putten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W.G. van Putten. The network helps show where John W.G. van Putten may publish in the future.

Co-authorship network of co-authors of John W.G. van Putten

This figure shows the co-authorship network connecting the top 25 collaborators of John W.G. van Putten. A scholar is included among the top collaborators of John W.G. van Putten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W.G. van Putten. John W.G. van Putten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy 2025 ·Acta Oncologica ·(unknown), (unknown), O. Chouvalova, Jan F. Ubbels, (unknown), T. Jeroen N. Hiltermann, (unknown), (unknown), (unknown), John W.G. van Putten, (unknown), Lisanne V. van Dijk, Johannes A. Langendijk, Robin Wijsman	1
2	The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study 2025 ·Clinical Lung Cancer ·(unknown), Rob ter Heine, (unknown), (unknown), (unknown), Bas Peters, Nienke A. G. Lankheet, (unknown), (unknown), Eric J. F. Franssen, (unknown), Cor H. van der Leest, (unknown), (unknown), (unknown), John W.G. van Putten, Ben E.E.M. van den Borne, Michel M. van den Heuvel, Maarten J. Deenen	0
3	External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy 2023 ·Radiotherapy and Oncology ·(unknown), A. van der Schaaf, Robin Wijsman, O. Chouvalova, Anthonie J. van der Wekken, (unknown), Remge M. Pieterman, John W.G. van Putten, (unknown), (unknown), Jan F. Ubbels, (unknown), Joachim Widder, Johannes A. Langendijk, Christina T. Muijs	5
4	Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report 2022 ·Journal of Medical Case Reports ·Marco van Londen, (unknown), (unknown), John W.G. van Putten, Wilbert M.T. Janssen	1
5	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma 2021 ·Lung Cancer ·(unknown), (unknown), (unknown), (unknown), Franz M.N.H. Schramel, Pepijn Brocken, John W.G. van Putten, Vincent van der Noort, G. Veerman, Stijn L.W. Koolen, Harry J.M. Groen, Anne‐Marie C. Dingemans, Ron H.J. Mathijssen, Egbert F. Smit, Joachim G.J.V. Aerts	1
6	Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer 2020 ·Pharmacoepidemiology and Drug Safety ·(unknown), Franz M.N.H. Schramel, Bas Peters, John W.G. van Putten, Olaf H. Klungel, Harry J.M. Groen, E.M.W. van de Garde, (unknown)	3
7	Effects of crizotinib on creatinine clearance and renal hemodynamics 2018 ·Lung Cancer ·(unknown), John W.G. van Putten, Wilbert M.T. Janssen	3
8	An instrument dedicated for modelling of pulmonary radiotherapy 2015 ·Radiotherapy and Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Jan F. Ubbels, (unknown), (unknown), Max Beijert, Harry J.M. Groen, J Kraan, T. Jeroen N. Hiltermann, Anthonie J. van der Wekken, John W.G. van Putten, (unknown), Remge M. Pieterman, (unknown), (unknown), Johannes A. Langendijk, Joachim Widder	8
9	Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome 2013 ·PLoS ONE ·(unknown), Ed Schuuring, (unknown), T. Jeroen N. Hiltermann, Remge M. Pieterman, (unknown), John W.G. van Putten, Jeroen J.W. Liesker, (unknown), Peter van Hengel, Inge Platteel, Wim Timens, Harry J.M. Groen	29
10	Iris Metastasis in Small-Cell Lung Carcinoma 2007 ·Journal of Thoracic Oncology ·(unknown), A.C.M. van den Bergh, John W.G. van Putten, Egbert F. Smit	8
11	Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancer 2004 ·Respiratory Medicine ·Henk Kramer, John W.G. van Putten, W. Rob Douma, (unknown), Hendrik M. van Dullemen, Harry J.M. Groen	12
12	Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC 2004 ·Lung Cancer ·Floris M Wachters, John W.G. van Putten, H. Marike Boezen, Harry J.M. Groen	8
13	Selective targeting of homologous DNA recombination repair by gemcitabine 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Floris M Wachters, John W.G. van Putten, Jan Gerard Maring, Małgorzata Z. Zdzienicka, Harry J.M. Groen, Harm H. Kampinga	64
14	A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. 2003 ·PubMed ·John W.G. van Putten, (unknown), (unknown), Anne Gregor, (unknown), Harry J.M. Groen	44
15	Activity of the combination of high-dose epirubicin with gemcitabine in advanced non-small-cell lung cancer 2001 ·Lung Cancer ·John W.G. van Putten	5
16	Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites 2001 ·Clinical Pharmacokinetics ·Thomas Kerbusch, Jan de Kraker, H.J. Keizer, John W.G. van Putten, Harry J.M. Groen, Rob L. H. Jansen, Jan H.M. Schellens, Jos H. Beijnen	101
17	Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer 2001 ·Lung Cancer ·John W.G. van Putten, Paul Baas, Henk Codrington, (unknown), Martín Müller, Neil K. Aaronson, Harry J.M. Groen	28
18	Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography breakdown → 2000 ·New England Journal of Medicine ·Remge M. Pieterman, John W.G. van Putten, J. J. Meuzelaar, Eduard L. Mooyaart, Willem Vaalburg, Gerard H. Koëter, V. Fidler, Jan Pruim, Harry J.M. Groen	864
19	Determination of Ifosfamide, 2- and 3-Dechloroethyifosfamide Using Gas Chromatography With Nitrogen-Phosphorus or Mass Spectrometry Detection 2000 ·Therapeutic Drug Monitoring ·Thomas Kerbusch, (unknown), (unknown), John W.G. van Putten, Alwin D. R. Huitema, Jos H. Beijnen	16
20	Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule 1999 ·Journal of Clinical Oncology ·Harry J.M. Groen, Eelco Fokkema, Bonne Biesma, (unknown), John W.G. van Putten, Pieter E. Postmus, Egbert F. Smit	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact